Evaluation of 11 SARS-CoV-2 antibody tests by using samples from patients with defined IgG antibody titers.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
07 04 2021
07 04 2021
Historique:
received:
15
01
2021
accepted:
25
03
2021
entrez:
8
4
2021
pubmed:
9
4
2021
medline:
27
4
2021
Statut:
epublish
Résumé
We evaluated the performance of 11 SARS-CoV-2 antibody tests using a reference set of heat-inactivated samples from 278 unexposed persons and 258 COVID-19 patients, some of whom contributed serial samples. The reference set included samples with a variation in SARS-CoV-2 IgG antibody titers, as determined by an in-house immunofluorescence assay (IFA). The five evaluated rapid diagnostic tests had a specificity of 99.0% and a sensitivity that ranged from 56.3 to 81.6% and decreased with low IFA IgG titers. The specificity was > 99% for five out of six platform-based tests, and when assessed using samples collected ≥ 22 days after symptom onset, two assays had a sensitivity of > 96%. These two assays also detected samples with low IFA titers more frequently than the other assays. In conclusion, the evaluated antibody tests showed a heterogeneity in their performances and only a few tests performed well with samples having low IFA IgG titers, an important aspect for diagnostics and epidemiological investigations.
Identifiants
pubmed: 33828214
doi: 10.1038/s41598-021-87289-6
pii: 10.1038/s41598-021-87289-6
pmc: PMC8027209
doi:
Substances chimiques
Antibodies, Viral
0
Immunoglobulin G
0
Types de publication
Evaluation Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7614Références
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
J Infect Dis. 2020 Jun 29;222(2):206-213
pubmed: 32427334
EBioMedicine. 2020 Sep;59:102915
pubmed: 32747185
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
medRxiv. 2022 May 18;:
pubmed: 32577692
Clin Microbiol Infect. 2020 Dec;26(12):1703-1705
pubmed: 32653658
PLoS Pathog. 2020 Sep 10;16(9):e1008796
pubmed: 32913364
J Clin Virol. 2020 Aug;129:104512
pubmed: 32563180
Clin Infect Dis. 2020 Nov 5;71(8):1930-1934
pubmed: 32306047
Ann Intern Med. 2020 Aug 18;173(4):262-267
pubmed: 32422057
J Infect. 2020 Aug;81(2):e55-e58
pubmed: 32335168
J Immunol. 2020 Nov 1;205(9):2437-2446
pubmed: 32878912
Signal Transduct Target Ther. 2020 Aug 14;5(1):156
pubmed: 32796814
J Clin Virol. 2020 Nov;132:104645
pubmed: 32961429
Nat Med. 2020 Aug;26(8):1200-1204
pubmed: 32555424
Nat Biotechnol. 2020 Oct;38(10):1174-1183
pubmed: 32855547
Clin Microbiol Infect. 2020 Oct;26(10):1386-1394
pubmed: 32603801
J Med Virol. 2020 Oct;92(10):1735-1738
pubmed: 32243608
J Clin Virol. 2020 Aug;129:104468
pubmed: 32485620
J Clin Microbiol. 2021 Apr 20;59(5):
pubmed: 33318065
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Nat Commun. 2020 Jul 6;11(1):3436
pubmed: 32632160
Lancet Infect Dis. 2020 Dec;20(12):1390-1400
pubmed: 32979318
J Clin Virol. 2020 Nov;132:104618
pubmed: 32919222
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Clin Chim Acta. 2020 Oct;509:288-292
pubmed: 32569631
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32350047
Clin Chim Acta. 2020 Nov;510:687-690
pubmed: 32910980
J Infect Dis. 2020 Sep 14;222(8):1280-1288
pubmed: 32761124
J Hosp Infect. 2020 Jun;105(2):348-349
pubmed: 32243951
J Clin Virol. 2020 Jul;128:104394
pubmed: 32416599
Clin Infect Dis. 2020 Nov 19;71(16):2066-2072
pubmed: 32357209
J Clin Lab Anal. 2020 Sep;34(9):e23411
pubmed: 32594577
Clin Chim Acta. 2020 Oct;509:1-7
pubmed: 32485157
Science. 2020 Jun 5;368(6495):1060-1061
pubmed: 32414781
N Engl J Med. 2020 Sep 10;383(11):1085-1087
pubmed: 32706954
ACS Nano. 2020 Apr 28;14(4):3822-3835
pubmed: 32223179